{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:16:45Z","timestamp":1777461405242,"version":"3.51.4"},"reference-count":11,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology"],"published-print":{"date-parts":[[2004]]},"abstract":"In the present study, we investigated the cardiovascular effects of centrally injected U-46619, a thromboxane A<sub>2<\/sub> (TXA<sub>2<\/sub>) analog, and the central and peripheral mechanisms of these effects in hemorrhagic shock conditions. Hemorrhage was performed by withdrawing a total volume of 2.1 ml of blood\/100 g body weight over a period of 10 min. Injections were made into the lateral cerebral ventricle (LCV), nucleus tractus solitarius (NTS), rostral ventrolateral medulla (RVLM) and paraventricular nucleus of hypothalamus (PVN). U-46619 (0.1, 1 and 2 \u00b5g) increased blood pressure and reversed hypotension in hemorrhagic shock. The pressor effect was dose- and time-dependent in all investigated brain areas. Heart rate changes were not significantly different in all groups. Pretreatment of rats with an injection of SQ-29548 (4 or 8\u00a0\u00b5g), a TXA<sub>2<\/sub> receptor antagonist, into the LCV, NTS, RVLM and PVN completely blocked the pressor effect of U-46619 (1 \u00b5g) injected into respective brain areas. Hemorrhage itself increased plasma adrenaline, noradrenaline, vasopressIN levels and renin activity. U-46619 (1 \u00b5g) injected into the LCV, PVN, RVLM and NTS produced additional increases in these hormone levels and in renin activity. Intravenous pretreatments of rats with prazosin (0.5 mg\/kg), an \u03b1<sub>1<\/sub>-adrenoceptor antagonist, [\u03b2-mercapto-\u03b2,\u03b2-cyclopentamethylenepropionyl<sup>1<\/sup>, O-Me-Tyr<sup>2<\/sup>,Arg<sup>8<\/sup>]- vasopressin (10 \u00b5g\/kg), a vasopressin V<sub>1<\/sub>-receptor antagonist, or saralasin (250 \u00b5g\/kg), an angiotensin II receptor antagonist, in hemorrhaged rats partially blocked the pressor response to U-46619 (1 \u00b5g) injected into the LCV, PVN, RVLM and NTS. Results show that centrally administered U-46619, a TXA<sub>2<\/sub> analog, increases blood pressure and reverses hypotension in hemorrhagic shock. Activation of central TXA<sub>2<\/sub> receptors mediates the pressor effect of the drug. Furthermore, the increases in plasma adrenaline, noradrenaline, vasopressin levels and renin activity are involved in these effects.<\/jats:p>","DOI":"10.1159\/000075546","type":"journal-article","created":{"date-parts":[[2004,3,2]],"date-time":"2004-03-02T16:06:30Z","timestamp":1078243590000},"page":"177-187","source":"Crossref","is-referenced-by-count":36,"title":["Restoration of Blood Pressure by Centrally Injected U-46619, a Thromboxane A<sub>2<\/sub> Analog, in Hemorrhaged Hypotensive Rats: Investigation of Different Brain Areas"],"prefix":"10.1159","volume":"70","author":[{"given":"Murat","family":"Yalcin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vahide","family":"Savci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2004,3,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1159\/000025327"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)02308-7"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/0031-9384(93)90020-G"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(03)02400-4"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(98)00133-X"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/0262-1746(85)90129-5"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(03)01602-9"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-3806(97)00030-8"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(99)00598-9"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)00987-6"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00166-I"}],"container-title":["Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/75546","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/75546","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:03:14Z","timestamp":1745467394000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000075546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":11,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2004,4,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000075546","archive":["Portico"],"relation":{},"ISSN":["0031-7012","1423-0313"],"issn-type":[{"value":"0031-7012","type":"print"},{"value":"1423-0313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004]]}}}